Use of Nusinersen in type 1 Spinal Muscular Atrophy. Literature Review
DOI:
https://doi.org/10.33448/rsd-v11i4.27297Keywords:
Spinal Muscular Atrophy; Infantile Spinal Muscular Atrophy; Werdnig-hoffmann Disease.Abstract
Type 1 spinal muscular atrophy is a neurodegenerative disease, caused by a deletion or mutation of the SMN1 gene. There is currently only one drug approved for its treatment in Brazil, which is nusinersen. The present study aimed to carry out a literature review to review the effectiveness of nusinersen in the treatment of type 1 spinal muscular atrophy. As well as, talk about the clinical studies carried out and the advances in treatment in terms of gain in motor milestone, motor function, use of mechanical ventilation and treatment safety. At the nusinersen group, 22% of babies achieved full head control, 10% were able to roll over, 8% were able to sit up independently and 1% managed to stand up; at the control group, no baby reached these Marcos. Regarding motor function, the scale was used CHOP-INTEND, which showed a score greater than 40, was seen in none of 13 babies with two copies of the gene at baseline and increased for seven of 13 participants at last visit in the 12 mg group.Overall, the risk of death or the use of permanent assisted ventilation was 47% lower in the nusinersen group than in the control group. The use of nusinersen proved to be effective in gaining motor milestones and using assisted ventilation, and even greater survival. However, it is tied to the onset of symptoms and the number of copies of the SMN2 gene. As for motor force, no study has been able to prove the return of motor force in its excellence.
References
Acsadi, G., Crawford, T. O., Müller‐Felber, W., Shieh, P. B., Richardson, R., Natarajan, N., Castro, D., Ramirez‐Schrempp, D., Gambino, G., Sun, P., & Farwell, W. (2021). Safety and efficacy of nusinersen in spinal muscular atrophy: The EMBRACE study. Muscle & Nerve, 63(5), 668–677. https://doi.org/10.1002/mus.27187
Albrechtsen, S. S., Alfred Peter Born, & Magnus Spangsberg Boesen. (2020). Nusinersen treatment of spinal muscular atrophy – a systematic review.
Aragon-Gawinska, K., Seferian, A. M., Daron, A., Gargaun, E., Vuillerot, C., Cances, C., Ropars, J., Chouchane, M., Cuppen, I., Hughes, I., Illingworth, M., Marini-Bettolo, C., Rambaud, J., Taytard, J., Annoussamy, M., Scoto, M., Gidaro, T., & Servais, L. (2018). Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study. Neurology, 91(14), e1312–e1318. https://doi.org/10.1212/WNL.0000000000006281
Araújo, A. P. de Q.-C., Ramos, V. G., & Cabello, P. H. (2005). Dificuldades diagnósticas na atrofia muscular espinhal. Arquivos de Neuro-Psiquiatria, 63(1), 145–149. https://doi.org/10.1590/S0004-282X2005000100026
Baioni, M. T. C., & Ambiel, C. R. (2010). Spinal muscular atrophy: Diagnosis, treatment and future prospects. Jornal de Pediatria, 86(4), 261–270. https://doi.org/10.2223/JPED.1988
Caetano, R., Hauegen, R. C., & Osorio-de-Castro, C. G. S. (2019). A incorporação do nusinersena no Sistema Único de Saúde: Uma reflexão crítica sobre a institucionalização da avaliação de tecnologias em saúde no Brasil. Cadernos de Saúde Pública, 35(8), e00099619. https://doi.org/10.1590/0102-311x00099619
Castiglioni, C., Levicán, J., Rodillo, E., Garmendia, M. A., Díaz, A., Pizarro, L., & Contreras, L. (2011). Atrofia muscular espinal: Caracterización clínica, electrofisiológica y molecular de 26 pacientes. Revista médica de Chile, 139(2), 197–204. https://doi.org/10.4067/S0034-98872011000200009
Claborn, M. K., Stevens, D. L., Walker, C. K., & Gildon, B. L. (2019). Nusinersen: A Treatment for Spinal Muscular Atrophy. Annals of Pharmacotherapy, 53(1), 61–69. https://doi.org/10.1177/1060028018789956
Espinosa, L. G. (2018). Síndrome de Werdnig-Hoffmann. 17(1), 1–8.
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C., Yamashita, M., Rigo, F., Hung, G., Schneider, E., Norris, D. A., Xia, S., Bennett, C. F., & Bishop, K. M. (2016). Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study. The Lancet, 388(10063), 3017–3026. https://doi.org/10.1016/S0140-6736(16)31408-8
Finkel, R. S., Chiriboga, C. A., Vajsar, J., Day, J. W., Montes, J., De Vivo, D. C., Bishop, K. M., Foster, R., Liu, Y., Ramirez-Schrempp, D., Schneider, E., Bennett, C. F., Wong, J., & Farwell, W. (2021). Treatment of infantile-onset spinal muscular atrophy with nusinersen: Final report of a phase 2, open-label, multicentre, dose-escalation study. The Lancet Child & Adolescent Health, 5(7), 491–500. https://doi.org/10.1016/S2352-4642(21)00100-0
Finkel, R. S., Mercuri, E., Darras, B. T., Connolly, A. M., Kuntz, N. L., Kirschner, J., Chiriboga, C. A., Saito, K., Servais, L., Tizzano, E., Topaloglu, H., Tulinius, M., Montes, J., Glanzman, A. M., Bishop, K., Zhong, Z. J., Gheuens, S., Bennett, C. F., Schneider, E., … De Vivo, D. C. (2017). Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. New England Journal of Medicine, 377(18), 1723–1732. https://doi.org/10.1056/NEJMoa1702752
Fortes-Rêgo, J. (1976). Doença de Werdnig-Hoffmann: Relato de dois casos. Arquivos de Neuro-Psiquiatria, 34(4), 387–393. https://doi.org/10.1590/S0004-282X1976000400011
Gómez, N. G., Vaillant, T. Z., Díaz, J. V., Massipe, E. R., & López, L. N. ([s.d.]). Atrofia muscular espinal en el niño. 6.
Licoviski, P. T., Bini, C. V., Turski, A. G., Bruno, G. K. de O., Borchardt, L. C., & Bini, A. C. D. (2021). Spinal Muscle Atrophy: Clinical Cases. Journal of Health Sciences, 23(2), 149–153. https://doi.org/10.17921/2447-8938.2021v23n2p149-153
Mercuri, E., B. T. Darras, D. A. Chiriboga, & J. W. Day. (2018, fevereiro 15). Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. 625–635.
Pires, M., Marreiros, H., Francisco, R. C., Soudo, A., & Vieira, J. P. ([s.d.]). ATROFIA MUSCULAR ESPINHAL. Acta Med Port., 8.
Polido, G. J., Miranda, M. M. V. de, Carvas Junior, N., Mendonça, R. de H., Caromano, F. A., Reed, U. C., Zanoteli, E., & Voos, M. C. (2019). Cognitive performance of children with spinal muscular atrophy: A systematic review. Dementia & Neuropsychologia, 13(4), 436–443. https://doi.org/10.1590/1980-57642018dn13-040011
Ramdas, S., & Servais, L. (2020). New treatments in spinal muscular atrophy: An overview of currently available data. Expert Opinion on Pharmacotherapy, 21(3), 307–315. https://doi.org/10.1080/14656566.2019.1704732
Reed, U. C., & Zanoteli, E. (2018). Therapeutic advances in 5q-linked spinal muscular atrophy. Arquivos de Neuro-Psiquiatria, 76(4), 265–272. https://doi.org/10.1590/0004-282x20180011
Silva, M. C. V. da, A. Przysiezny, & O. J. Capellani. (2013). Síndrome de Werdnig-Hoffman (amiotrofia espinal do tipo 1): Relato de caso. 42(1), 96–99.
Silvinato, A., & Bernardo, W. M. (2018). Spinal muscular atrophy 5Q – Treatment with nusinersen. Revista da Associação Médica Brasileira, 64(6), 484–491. https://doi.org/10.1590/1806-9282.64.06.484
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Mirella Viviani Amaral Assis Belizário; Juliana Ferreira Ura Berlanga; Cláudia Elaine Cestari Souza; Cláudia Maria Dias Moreira; Marillis Mesquita Gonçalves de Arruda; Nathália de Oliveira; Maria Inês Vaz de Oliveira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
